Dapagliflozin in patients with cardiometabolic risk factors, effectiveness of COVID-19 vaccines against the Delta variant

Peer reviewed journals featured:

- A randomised controlled trial of dapagliflozin in patients with cardiometabolic risk factors (DARE-19) hospitalised with COVID-19 [here] and associated commentary [here]
- A narrative review on the implementation of a paediatric Head Injury Discharge At Triage (HIDAT) tool during the COVID-19 pandemic [here]
- Observational studies on:
  - Effectiveness of COVID-19 vaccines against the Delta variant [here]
  - Association between COVID-19 exposure and self-reported compliance among higher education employees in the US [here]
- Commentary on:
  - Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus [here]
  - The landscape of COVID-19 trials in Australia [here]
  - SARS-CoV-2 human challenge studies [here]
- A case report of cerebral venous sinus thrombosis after resolution of COVID-19 in a non-hospitalised patient [here]

Letters and correspondence discussed:

- Household transmission of SARS-CoV-2 from children and adolescents [here]

News and blogs

- In India, two-thirds of people carry antibodies, the death toll may be 10 times the official figure [here]
- NEJM audio interview on the impact of COVID-19 on trainees and junior faculty [here]

Click here to subscribe to the daily evidence digest.